Showing 951-960 of 1226 results for "".
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b
- New Data Back Ability of Pfizer, BioNTech’s COVID-19 Vaccine to Foil UK Strainhttps://modernod.com/news/new-data-back-ability-of-pfizer-biontechs-covid-19-vaccine-to-foil-uk-strain/2478782/Pfizer and BioNTech on Wednesday reported results from another in-vitro study indicating that their COVID-19 vaccine BNT162b2 is likely capable of neutralizing the rapidly spreading UK strain of SARS-CoV-2, also known as B.1.1.7. The findings, which were published on the preprint server bioRxiv,
- Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Datahttps://modernod.com/news/graybug-vision-completes-treatment-phase-of-altissimo-trial-in-wet-amd-with-12-month-topline-data/2478738/Graybug Vision announced the last patient visit in its GB-102 phase 2b ALTISSIMO core trial (the 12-month treatment phase) in wet age-related macular degeneration (AMD). ALTISSIMO 12-month topline data are expected to be announced in the second quarter of 2021, with full results to b
- Oyster Point Submits NDA to FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-submits-nda-to-fda-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478677/Oyster Point Pharma announced it has submitted a 505(b)(2) new drug application (NDA) to the FDA for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The NDA submission is supported by safety and efficacy results from the phase 3 ONSET-2, phase 2b ONSET-
- Novaliq Announces First Patient Randomized in the ESSENCE-2 Phase 3 Trial of Dry Eye Treatment CyclASolhttps://modernod.com/news/novaliq-announces-first-patient-randomized-in-the-phase-3-trial-essence-2-of-dry-eye-treatment-cyclasol/2478637/Novaliq announced that it has initiated the randomization of patients in its phase 3 clinical trial ESSENCE-2 that is designed to replicate efficacy results of the previous phase 2/3 ESSENCE-1 trial. “The initiation of this second registrational trial represents a key milestone for b
- Zeiss Partners With Microsoft for Better Patient Care Through Data-Driven Health Carehttps://modernod.com/news/zeiss-partners-with-microsoft-for-better-patient-care-through-data-driven-health-care/2478383/Zeiss Group and Microsoft announced a multi-year strategic partnership to accelerate Zeiss’ transformation into a digital services provider that is embracing a cloud-first approach. By standardizing its equipment and processes on Microsoft Azure as its preferred cloud platform, Zeiss will b
- Samsung Bioepis Initiates Phase 3 Clinical Trial for SB15, Proposed Biosimilar to Eylea (Aflibercept)https://modernod.com/news/samsung-bioepis-initiates-phase-3-clinical-trial-for-sb15-proposed-biosimilar-to-eylea-aflibercept/2477950/Samsung Bioepis announced the initiation of phase 3 clinical trial for SB15, the company’s proposed biosimilar referencing Eylea (aflibercept). The trial is a randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity b
- Viela Bio Announces FDA Approval of Uplinza (Inebilizumab) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/viela-bio-announces-fda-approval-of-uplinza-inebilizumab-for-the-treatment-of-neuromyelitis-optica-spectrum-disorder-nmosd/2477912/Viela Bio announced the FDA approval of Uplizna (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD). The monotherapy drug is the first and only B cell-depleting antibody approved for the disease. Uplizna is indicated for those who are
- Mojo Vision Raises Additional $51 Million to Develop Smart Contact Lenshttps://modernod.com/news/mojo-vision-raises-additional-51-million-to-develop-smart-contact-lens/2477678/Mojo Vision announced it has raised more than $51 million in a Series B-1 investment round to propel the development of its smart contact lens, Mojo Lens. This new round brings Mojo Vision’s total funding to date to more than $159 million. In January, Mojo announced that it is in th
- CMS Reevaluates Accelerated Payment Program and Suspends Advance Payment Programhttps://modernod.com/news/cms-suspends-advance-payments-to-providers-is-reevaluating-accelerated-payments-for-hospitals/2477652/The Centers for Medicare & Medicaid Services (CMS) announced that it is reevaluating the amounts that will be paid under its Accelerated Payment Program and suspending its Advance Payment Program to Part B suppliers effective immediately. The agency made this announcement following the paymen